1. Home
  2. LKFT vs IOVA Comparison

LKFT vs IOVA Comparison

Compare LKFT & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lakefront Biotherapeutics American Depositary Shares

LKFT

Lakefront Biotherapeutics American Depositary Shares

N/A

Current Price

$28.13

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$4.72

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LKFT
IOVA
Founded
N/A
2007
Country
Belgium
United States
Employees
452
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
2015
2008

Fundamental Metrics

Financial Performance
Metric
LKFT
IOVA
Price
$28.13
$4.72
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
$9.00
AVG Volume (30 Days)
149.8K
16.1M
Earning Date
N/A
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
14.84
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$47.74
Revenue Next Year
N/A
$40.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$27.75
$1.76
52 Week High
$30.91
$5.64

Technical Indicators

Market Signals
Indicator
LKFT
IOVA
Relative Strength Index (RSI) 40.05 52.37
Support Level N/A $3.77
Resistance Level $30.25 $5.63
Average True Range (ATR) 0.56 0.40
MACD -0.24 0.01
Stochastic Oscillator 10.77 48.83

Price Performance

Historical Comparison
LKFT
IOVA

About LKFT Lakefront Biotherapeutics American Depositary Shares

Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Share on Social Networks: